Abzena (LON:ABZA)‘s stock had its “buy” rating reaffirmed by investment analysts at Numis Securities in a research note issued on Wednesday. They presently have a GBX 80 ($1.08) target price on the stock. Numis Securities’ target price would suggest a potential upside of 149.84% from the company’s previous close.

Separately, FinnCap reissued a “buy” rating and set a GBX 70 ($0.94) price target on shares of Abzena in a report on Monday.

Abzena (ABZA) traded down GBX 0.98 ($0.01) on Wednesday, reaching GBX 32.02 ($0.43). The company had a trading volume of 2,346 shares, compared to its average volume of 123,688. Abzena has a fifty-two week low of GBX 27.73 ($0.37) and a fifty-two week high of GBX 66 ($0.89).

COPYRIGHT VIOLATION NOTICE: This piece was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be read at https://www.thecerbatgem.com/2017/12/15/numis-securities-reiterates-buy-rating-for-abzena-abza.html.

About Abzena

Abzena plc is a life sciences company. The Company provides technologies and complementary services to enable the development and manufacture of biopharmaceutical products. It has a global customer base which includes approximately 20 biopharmaceutical companies, as well as large and small biotech companies and academic groups.

Receive News & Stock Ratings for Abzena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abzena and related stocks with our FREE daily email newsletter.